Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease (COPD)
Pharma
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
The FDA has requested more efficacy data for Sanofi and Regeneron's Dupixent in COPD. Additionally, Eylea sales fell by 2% in the first quarter.
Kevin Dunleavy
May 2, 2024 12:00pm
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm
GSK sets $35 out-of-pocket price cap for its inhalers in the US
Mar 21, 2024 11:45am
AstraZeneca caps out-of-pocket inhaler costs at $35 in the US
Mar 18, 2024 11:02am
FDA speeds Sanofi, Regeneron's application for Dupixent in COPD
Feb 22, 2024 11:25pm
Theravance's COPD med Yupelri flunks head-to-head study
Jan 5, 2024 10:14am